Event Overview

Cancer drug development tends to focus on inhibiting protein activity rather than modulating protein levels. While this approach has seen some success, it comes with challenges, such as long-term resistance and toxicity. Targeted protein degradation offers a potential solution to this problem.

Protein degraders are small molecules that induce degradation and remove deleterious proteins from afflicted cells by modulating E3 ligase ubiquitination activity. In this webinar brought to you by The Scientist and sponsored by PerkinElmer|Cisbio, researchers will discuss how small-molecule degraders work, key points of interest in their design, and their applications in both the laboratory and the clinic.

Topics to be covered
  • Using proteolysis targeting chimera (PROTAC) technology to overcome on-target toxicity of anticancer agents
  • Structure-based design approaches for developing PROTACs against cancer
  • Thursday, November 19, 2020
    2:30 - 4:00 PM, Eastern Time


    Daohong Zhou, MD
    Professor of Pharmacodynamics and Radiation Oncology
    Harry E. Innes Endowed Professor of Cancer Research
    Associate Director for Translation and Drug Development
    University of Florida Health Cancer Center
    University of Florida at Gainesville

    Aileen Frost, PhD
    Alessio Ciulli Research Group
    Medicinal Chemist and Organic Chemistry Scientist
    Biological Chemistry and Drug Discovery, School of Life Sciences
    University of Dundee

    Register Now

    Optimizing Lab Ultrafiltration Workflows: From Molecule Separation to Diagnostics

    You must have Javascript and Cookies enabled to access this webcast.

    Information you provide will be held in confidence and will be shared with the sponsoring vendor(s) of this webinar. The Scientist and sponsor(s) may use the information to contact you about your account and to let you know about related programs and products; you may opt-out at any time. This allows The Scientist to keep these webinars free of charge for our readers.